Enhanced passive safety surveillance of a trivalent and a quadrivalent influenza vaccine in Denmark and Finland during the 2018/2019 season

References

• World Health Organization. Vaccines against influenza WHO position paper - November 2012. Wkly Epidemiol Rec. 2012;87:461–76.
   PubMedGoogle Scholar
• European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC). Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU. London; 2014 Apr 10 [accessed 2019 Oct 14]. https://www.ema.europa.eu/en/interim-guidance-enhanced-safety-surveillance-seasonal-influenza-vaccines-eu.
   Google Scholar
• Clothier HJ, Selvaraj G, Easton ML, Lewis G, Crawford NW, Buttery JP. Consumer reporting of adverse events following immunization. Hum Vaccin Immunother. 2014;10:3726–30. doi:10.4161/hv.34369.
   PubMed Web of Science ®Google Scholar
• Clothier HJ, Crawford NW, Kempe A, Buttery JP. Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria. Commun Dis Intell Q Rep. 2011;35:294–98.
   PubMedGoogle Scholar
• Alicino C, Merlano C, Zappettini S, Schiaffino S, Della Luna G, Accardo C, Gasparini R, Durando P, Icardi G. Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety. Hum Vaccin Immun. 2015;11:91–94. doi:10.4161/hv.34360.
   PubMed Web of Science ®Google Scholar
• Haugh M, Gresset-Bourgeois V, Macabeo B, Woods A, Samson SI. A trivalent, inactivated influenza vaccine (Vaxigrip(R)): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries. Expert Rev Vacc. 2017;16:545–64. doi:10.1080/14760584.2017.1324302.
   PubMed Web of Science ®Google Scholar
• Bricout H, Chabanon AL, Souverain A, Sadorge C, Vesikari T, Caroe TD. Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16. Euro Surveill. 2017;18:22.
   Google Scholar
• Chabanon AL, Bricout H, Ballandras C, Souverain A, Caroe TD, Butler KM. Report from enhanced safety surveillance of two influenza vaccines (Vaxigrip and Intanza 15 µg) in two European countries during influenza season 2016/17 and comparison with 2015/16 season. Hum Vaccin Immun. 2018;14:378–85. doi:10.1080/21645515.2017.1405882.
   PubMed Web of Science ®Google Scholar
• Gandhi-Banga S, Chabanon AL, Eymin C, Caroe T, Butler K, Moureau A. Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season. Hum Vaccin Immun. 2019;15:1–5. doi:10.1080/21645515.2019.1581538.
   PubMed Web of Science ®Google Scholar
• World Medical Association. Declaration of Helsinki; [ accessed 2020 Jun 11]. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/.
   Google Scholar
• Hoffmann W, Latza U, Baumeister SE, Brünger M, Buttmann-Schweiger N, Hardt J, Hoffmann V, Karch A, Richter A, Schmidt CO, et al. Guidelines and recommendations for ensuring Good epidemiological practice (GEP): a guideline developed by the German society for epidemiology. Eur J Epidemiol. 2019;34:301–17. doi:10.1007/s10654-019-00500-x.
   PubMed Web of Science ®Google Scholar
• European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ENCePP guide on methodological standards in pharmacoepidemiology; [accessed 2020 Jun 11]. http://www.encepp.eu/standards_and_guidances/methodologicalGuide.shtml.
   Google Scholar
• Datapharm Electonic Medicines Compendium. Summary of product characteristics: quadrivalent influenza vaccine (Split virion, inactivated); 2019 May 29 [accessed 2019 Oct 14]. https://www.medicines.org.uk/emc/product/666/smpc.
   Google Scholar
• Gresset-Bourgeois V, Leventhal PS, Pepin S, Hollingsworth R, Kazek-Duret MP, De Bruijn I, Samson SI. Quadrivalent inactivated influenza vaccine (VaxigripTetra). Expert Rev Vaccines. 2018;17:1–11. doi:10.1080/14760584.2018.1407650.
   PubMed Web of Science ®Google Scholar
• de Lusignan S, Ferreira F, Damaso S, Byford R, Pathirannehelage S, Yeakey A, Yonova I, Schuind A, Dos Santos G. Enhanced passive surveillance of influenza vaccination in England, 2016-2017- an observational study using an adverse events reporting card. Hum Vaccin Immunother. 2019;15:1048–59. doi:10.1080/21645515.2019.1565258.
   PubMed Web of Science ®Google Scholar
• de Lusignan S, Dos Santos G, Byford R, Schuind A, Damaso S, Shende V, McGee C, Yonova I, Ferreira F. Enhanced safety surveillance of seasonal quadrivalent influenza vaccines in english primary care: interim analysis. Adv Ther. 2018;35:1199–214. doi:10.1007/s12325-018-0747-4.
   PubMed Web of Science ®Google Scholar
• Huang C, Fu X, Zhou Y, Mi F, Tian G, Liu X, Wu J, Ding C, Yan D, Li L, et al. Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents. Vaccine. 2020;38:1332–44. doi:10.1016/j.vaccine.2019.11.071.
   PubMed Web of Science ®Google Scholar
• Vaccines Today. Finland: no jab, no job? 2019 Dec 21 [accessed 2019 Oct 14]. https://www.vaccinestoday.eu/stories/finland-no-jab-no-job/.
   Google Scholar
• Larson H, de Figueiredo A, Karafllakis E, Rawal M The state of vaccine confidence in the EU: 2018. Luxembourg; [accessed 2019 Oct 14]. https://ec.europa.eu/health/sites/health/files/vaccination/docs/2018_vaccine_confidence_en.pdf.
   Google Scholar
• Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, et al. Surveillance for safety after immunization: vaccine adverse event reporting system (VAERS)–United States, 1991-2001. MMWR Surveill Summ. 2003;52:1–24.
   PubMedGoogle Scholar
• Clothier HJ, Crawford NW, Russell M, Buttery JP. Adverse events following vaccination of older people may be under-reported. Med J Aust. 2017;207:301–02. doi:10.5694/mja16.01371.
   PubMed Web of Science ®Google Scholar
• Pillsbury AJ, Glover C, Jacoby P, HE Q, Fathima P, Cashman P, Leeb A, Blyth CC, Gold MS, Snelling T, et al. Active surveillance of 2017 seasonal influenza vaccine safety: an observational cohort study of individuals aged 6 months and older in Australia. BMJ Open. 2018;8:e023263. doi:10.1136/bmjopen-2018-023263.
   PubMed Web of Science ®Google Scholar